Five features of nebivolol use Review article

Article Sidebar

Requires Subscription PDF (Język Polski)


Published: Dec 31, 2019
Keywords:
nebivolol, indications, special clinical situations

Main Article Content

Marcin Grabowski
I Katedra i Klinika Kardiologii, Warszawski Uniwersytet Medyczny

Abstract

Nebivolol is a β1-cardioselective β-blocker with vasodilating properties. Current guidelines prefer the use of such β-blockers in hypertension. Recently, selected nebivolol tablets have obtained registrations for use in coronary artery disease. The article presents selected clinical situations that may justify the preference for using this drug. Nebivolol belongs to the third generation of β-blockers used in the treatment of hypertension and combines two preferred pharmacological features today, which are vasodilation and cardioselectivity. These features provide effective lowering of blood pressure, reduction of heart rate, avoidance of adverse metabolic effect and most side effects.

Downloads

Download data is not yet available.

Article Details

How to Cite
Grabowski , M. (2019). Five features of nebivolol use. Cardiology in Practice, 13(3-4), 18-20. Retrieved from https://journalsmededu.pl/index.php/kwp/article/view/1182
Issue
Vol 13 No 3-4 (2019)
Section
Pharmacology in cardiological practice
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Mancia G., De Backer G., Dominiczak A. et al.: 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 2007; 28: 1462-1536.
2. Williams B., Mancia G., Spiering W. et al.; ESC Scientific Document Group: 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur. Heart J. 2018; 39(33): 3021-3104.
3. Mancia G., Fagard R., Narkiewicz K. et al.; Grupa Robocza ESH i ESC do spraw postępowania w nadciśnieniu tętniczym: Wytyczne ESH/ESC dotyczące postępowania w nadciśnieniu tętniczym w 2013 roku. Kardiologia Polska 2013; 71(3): 27-118.
4. Tykarski A., Filipiak K.J., Januszewicz A. et al. (red.): Zasady postępowania w nadciśnieniu tętniczym – 2019 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze w Praktyce 2019; 5(1): 1-86.
5. Grabowski M.: Nebiwolol – 33 pytania i odpowiedzi. Medical Education, Warszawa 2009: 1-56.
6. Charakterystyka produktu leczniczego Nedal.